Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer - Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY)

The Phase 3 trial of Sanofi SA SNY and Regeneron Pharmaceuticals Inc's REGN Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC).
These data are planned to form the basis of regulatory submissions in the U.S. and European Union.
In this top-line initial analysis of 466 patients, combining Libtayo with chemotherapy reduced the risk of death by 29% compared to chemotherapy alone.
Median OS was 22 months for Libtayo/chemo combo and 13 months for chemotherapy alone.
No new Libtayo safety signals were identified.
Price Action: REGN shares are up 2.45 at $594.75, and SNY stock is up 1.1% at $50.45 during the premarket session on the last check Thursday.